Four Seasons Ventures

Four Seasons Ventures

Four Seasons Ventures (FSV) operates at the intersection of national security research and private capital, sourcing its pipeline from US Government laboratories. The firm was founded to solve a persistent structural problem: commercially viable technologies developed with federal R&D dollars stall on the lab bench when grant funding ends and no private-sector champion steps forward. FSV inserts itself at that inflection point, providing equity capital and a management team to transition government-originated IP into products for both public and private sector buyers. The firm’s investment strategy is built around a single, unconventional sourcing model rather than traditional buyout or venture stage mandates. FSV targets technologies that carry continuing federal agency support — a proxy for technical validation and early customer demand — and takes an active role in shaping the commercial pathway. Asset classes are implicit in the technology verticals that populate national security research: advanced materials, AI/ML, cybersecurity, industrial sensing, robotics, and space-adjacent hardware. The firm has stated it optimizes for the point where development risk and commercial readiness offer its target risk-return tradeoff, though the website now notes FSV is not making any new investments at this time. FSV runs out of a primary office at 1055 Thomas Jefferson Street NW in Washington, DC, with an off-site address in Atlanta, Georgia. Principals, team size, and assets under management are not publicly disclosed. No adjacent philanthropic foundations, parallel fund structures, or co-investment club affiliations are visible in available records. FSV’s declared posture — no new investments — is the most significant operational signal in recent years, though no dated announcement accompanies the website language. FSV’s architecture departs from a standard PE firm in its exclusive reliance on USG lab-originated deal flow. This creates a sourcing moat inaccessible to most capital allocators but also makes the firm a function of federal research priorities and contracting cycles. Governance and succession details are absent from public sources, leaving the firm as an opportunistic vehicle whose next chapter remains tied to shifts in national security R&D budgets or a reversal of its current no-new-investment stance.